These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26448437)

  • 1. Monoconjugation of Human Amylin with Methylpolyethyleneglycol.
    Sisnande T; Guerreiro LH; Braga RR; Jotha-Mattos L; Erthal LC; Tinoco P; Ferreira BM; Lima LM
    PLoS One; 2015; 10(10):e0138803. PubMed ID: 26448437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and characterization of PEGylated amylin.
    Guerreiro LH; Guterres MF; Melo-Ferreira B; Erthal LC; Rosa Mda S; Lourenço D; Tinoco P; Lima LM
    AAPS PharmSciTech; 2013 Sep; 14(3):1083-97. PubMed ID: 23818080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amylin conjugation with methoxyl polyethyleneglycol.
    Guterres MF; Guerreiro LH; Melo-Ferreira B; Erthal LC; Lima LM
    Protein Pept Lett; 2013 Nov; 20(11):1264-71. PubMed ID: 23855659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physico-chemical stability of co-formulation of PEGylated human amylin with insulin.
    Sinésia C; do Nascimento CVMF; Lacativa PGS; Lima LMTR
    Pharm Dev Technol; 2019 Oct; 24(8):975-981. PubMed ID: 31124388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of amylin and amylin deficiency.
    Kruger DF; Gatcomb PM; Owen SK
    Diabetes Educ; 1999; 25(3):389-97; quiz 398. PubMed ID: 10531859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amylin induces hypoglycemia in mice.
    Guerreiro LH; Da Silva D; Sola-Penna M; Mizurini DM; Lima LM
    An Acad Bras Cienc; 2013 Mar; 85(1):349-54. PubMed ID: 23460444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular confinement of human amylin in lipidic nanoparticles.
    Braga RR; Almeida L; Guerreiro LH; Tinoco P; Miranda KR; Braga CA; Gadelha AP; Garcia S; Lima LM
    J Liposome Res; 2016 Sep; 26(3):188-98. PubMed ID: 26340033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
    Edelman SV; Weyer C
    Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats.
    Nascimento CVMF; Sinezia C; Sisnande T; Lima LMTR; Lacativa PGS
    Peptides; 2019 Apr; 114():44-49. PubMed ID: 30995454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Cagrilintide, a Long-Acting Amylin Analogue.
    Kruse T; Hansen JL; Dahl K; Schäffer L; Sensfuss U; Poulsen C; Schlein M; Hansen AMK; Jeppesen CB; Dornonville de la Cour C; Clausen TR; Johansson E; Fulle S; Skyggebjerg RB; Raun K
    J Med Chem; 2021 Aug; 64(15):11183-11194. PubMed ID: 34288673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of amylin in glucose homeostasis and its perspective use in diabetes management].
    Otto-Buczkowska E; Mazur-Dworzecka U; Dworzecki T
    Przegl Lek; 2008; 65(3):135-9. PubMed ID: 18624122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Amylin in Type 1 and Type 2 Diabetes.
    Hieronymus L; Griffin S
    Diabetes Educ; 2015 Dec; 41(1 Suppl):47S-56S. PubMed ID: 26424675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
    Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
    Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
    Gingell JJ; Burns ER; Hay DL
    Endocrinology; 2014 Jan; 155(1):21-6. PubMed ID: 24169554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.
    Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC
    Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.
    Gault VA; Kerr BD; Irwin N; Flatt PR
    Biochem Pharmacol; 2008 Jun; 75(12):2325-33. PubMed ID: 18455149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloidogenesis of the amylin analogue pramlintide.
    da Silva DC; Fontes GN; Erthal LC; Lima LM
    Biophys Chem; 2016 Dec; 219():1-8. PubMed ID: 27665170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
    Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
    Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric particles for the controlled release of human amylin.
    Guerreiro LH; Da Silva D; Ricci-Junior E; Girard-Dias W; Mascarenhas CM; Sola-Penna M; Miranda K; Lima LM
    Colloids Surf B Biointerfaces; 2012 Jun; 94():101-6. PubMed ID: 22326343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.